文献速递鼻科

单核苷酸多态性对慢性鼻窦炎疗效的影响:一项初步观察性研究

Influence of Single Nucleotide Polymorphisms on CRS Outcomes: A Preliminary Observational Study.
PubMed 文献 · Laryngoscope · 2024-08-22

这项前瞻性研究纳入48名受试者,包括32例慢性鼻窦炎(CRS)患者和16名健康对照,CRS患者按EPOS指南接受度普利尤单抗治疗或内镜手术。研究发现两种治疗均显著降低鼻息肉评分(NPS),手术效果更优,而度普利尤单抗显著改善嗅觉识别测试(SIT)评分。rs1800629(TNFA)、rs2856838(IL1a)、rs17561(IL1a)和rs1805011(IL4R)等SNP位点分布存在显著差异,部分位点表达与治疗结局相关。

要点

  • 度普利尤单抗和内镜手术均显著降低NPS,手术组结果更优,度普利尤单抗组SIT评分显著改善。
  • rs2856838和rs1805011变异在度普利尤单抗组与显著更好的SIT和SNOT-22结局相关。
  • 手术组中表达rs2856838变异的患者SNOT-22评分显著改善。

核心结论

  • 这些初步发现提示SNP基因型可能指导CRS的个体化治疗策略,需要进一步更大规模的前瞻性研究来证实这些初步观察结果。

研究设计与样本

  • 前瞻性研究纳入48名受试者,包括32例CRS患者和16名健康对照;CRS患者根据EPOS指南接受度普利尤单抗治疗或内镜手术,采用TaqMan SNP基因分型技术鉴定SNP变异,随访6个月评估症状评分、NPS和SNP谱。

主要发现

  • 度普利尤单抗治疗和内镜手术均显著降低NPS,手术组结果更优;度普利尤单抗治疗显著改善SIT评分。
  • SNP谱存在显著差异,特别是rs1800629(TNFA)、rs2856838(IL1a)、rs17561(IL1a)和rs1805011(IL4R)。
  • 度普利尤单抗组中rs2856838和rs1805011变异表达者较非表达者SIT和SNOT-22结局显著更好。
  • 手术组中表达rs2856838变异的患者SNOT-22评分显著改善。

关键数值与推荐

  • 主要指标包括鼻息肉评分(NPS)、嗅觉识别测试(SIT)评分和SNOT-22结局,在6个月随访时评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文自述为初步研究,需要进一步更大规模的前瞻性研究来证实这些初步观察结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE(S): To conduct a preliminary investigation into the relationship between specific SNP variants, type II inflammation, and the effectiveness of dupilumab therapy and surgery in patients with CRS. METHODS: In this prospective study, 48 subjects were enrolled, comprising 32 CRS patients and 16 healthy controls. The CRS patients were subjected to either dupilumab therapy or endoscopic surgery according to EPOS guidelines. SNP variants were identified using the TaqMan SNP genotyping technique. The identified SNP profiles were compared between the control group and CRS patients, and their potential influence on treatment outcomes was evaluated. Treatment responses were assessed based on symptom scores, such as SS-I, SNOT-22, disease progression using the NPS findings, and SNP profiles at a 6-month follow-up. The primary measures included the Nasal Polyp Score, Smell Identification Test (SIT) score, and SNOT-22 outcomes. RESULTS: Dupilumab therapy and surgery significantly decreased NPS, with the last showing superior results. However, dupilumab therapy resulted in a significantly improved SIT score. Significant differences were observed in SNP profiles, particularly with rs1800629 (TNFA), rs2856838 (IL1a), rs17561 (IL1a), and rs1805011 (IL4R). In particular, the expression of rs2856838 and rs1805011 variants in the dupilumab group was associated with significantly better SIT and SNOT-22 outcomes than non-expressors. Also, the surgery group patients expressing the rs2856838 variant reported significant improvements in SNOT-22 scores. CONCLUSION: These preliminary findings suggest that SNP genotypes may guide personalized treatment strategies for CRS. Further larger prospective studies are required to confirm these initial observations. LEVEL OF EVIDENCE: 2 Laryngoscope, 135:570-578, 2025.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Maniaci A, Bonacci P, Stefani S, et al. Influence of Single Nucleotide Polymorphisms on CRS Outcomes: A Preliminary Observational Study. Laryngoscope. 2024. PMID: 39172010. doi:10.1002/lary.31719

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。